GLP-1 Drug Calls: A New Category of Practice Administrative Burden

What 3.37 Million Patient Calls Reveal About GLP-1 Drug Requests

GLP-1 medications — semaglutide and tirzepatide brands like Ozempic, Wegovy, Mounjaro, and Zepbound — have moved from a niche endocrinology prescription to a request practices field across nearly every specialty: primary care, OB/GYN, cardiology, internal medicine, and weight-management clinics alike. Anecdotally, front desk staff have been saying these calls take longer and involve more back-and-forth than a typical refill. We wanted to know whether that was actually true, and if so, why.

At CallMyDoc, we mined 3,365,339 transcribed patient calls handled across our platform between January 2025 and August 2026, using a keyword classifier (ozempic, wegovy, mounjaro, zepbound, semaglutide, tirzepatide, saxenda, trulicity, and general weight-loss-drug terms) to isolate the GLP-1-related subset. The result: 21,250 calls, or 0.6% of total call volume — a real, measurable category, not a rounding error, and one that does not overlap with anything else we have published.

A New Call Category, Not Yet a Flood

Before anything else, it is worth being precise about scale and trend — because the easy, dramatic headline here is not the accurate one.

GLP-1 call volume has been remarkably flat as a share of total calls: roughly 0.55–0.70% of monthly volume for eighteen straight months, from January 2025 through June 2026. In the most recent two months of data (July–August 2026), that share ticked up to 0.75–0.83% — a real but modest increase, and thin: two data points is a signal worth watching, not a trend worth declaring. Looked at as monthly call counts, GLP-1-related calls averaged 985 per month in 2025 and 1,178 per month across January–August 2026 — a 19.6% increase, real but not the multi-x growth story a less careful read of the data might suggest.

So: GLP-1 calls are a small, stable-to-slightly-growing share of total volume. What makes them worth a practice’s attention is not their size. It is their shape.

GLP-1 Calls Aren’t Bigger Refill Calls — They’re a Different Administrative Pattern

Compared to the baseline mix of all 3.37 million calls in the dataset, GLP-1-related calls skew dramatically toward three specific administrative categories:

Two things stand out. First, nearly half of all GLP-1 calls (48.1%) touch refill logistics — more than three times the baseline rate. Second, and more tellingly, GLP-1 calls are notably lower than baseline on plain billing and payment questions (1.0% vs. 2.8%). Put those together and a clear pattern emerges: this is not a payment-collection problem. It is an access and authorization friction pattern — refill requests that get tangled up with insurance-coverage verification and prior-authorization paperwork, often for the same patient, often on the same call or a follow-up call days later.

Why Insurance and Prior Authorization Dominate These Calls

GLP-1 drugs carry list prices in the hundreds of dollars per month, and insurance coverage for weight-management indications specifically (as opposed to diabetes indications) varies widely by plan — and changes frequently as payers update formularies. That combination produces exactly the pattern in the data: a patient calls for a routine refill, learns their coverage has changed or a prior authorization has expired, and the practice’s staff has to re-verify coverage and re-submit authorization paperwork before the refill can proceed.

To be precise about where CallMyDoc fits in that workflow: our platform captures, transcribes, and routes these calls with full context to the right staff member or provider — it does not adjudicate prior authorizations, which is a decision made by the insurer, not the practice or its call platform. What CallMyDoc eliminates is the manual capture-and-relay step: the front desk no longer has to take a message, guess at the medication and pharmacy details, and route it by hand. The AI identifies the patient, transcribes the request verbatim, and creates a structured task with full context — the same infrastructure behind CallMyDoc’s broader prescription-refill automation.

That compounding effect matters operationally. A standard prescription refill request already touches multiple staff members before it is resolved — front desk intake, nursing review, provider sign-off, and a callback to the patient or pharmacy. A GLP-1 refill call that also requires insurance re-verification and a prior-authorization resubmission adds an entirely separate workflow on top of that: someone has to check current coverage, confirm whether a PA is on file or expired, and often follow up with the payer directly. That is why the category shows up so heavily in the data as refill-plus-insurance-plus-PA rather than any one of those in isolation.

The Operational Implication for Practices

Refill logistics, insurance verification, and prior-authorization routing are precisely the categories of call that structured capture and routing handle well — they follow a predictable shape even when the underlying insurance situation is messy. That is consistent with what CallMyDoc already does across its broader call volume: the platform automates 47% of patient calls today, concentrated in exactly these kinds of structured, repeatable request types.

For a practice that prescribes GLP-1 medications at any real volume — endocrinology, primary care, OB/GYN, cardiology, and weight-management clinics in particular — the practical takeaway is that these calls deserve their own routing path rather than being lumped into a generic “medication questions” bucket. A GLP-1 refill call very often needs insurance and prior-authorization context attached from the first touch, not discovered three steps into the workflow.

What This Means for Your Practice

• If you prescribe GLP-1 medications, expect a distinct call pattern — heavier on refill-plus-insurance-plus-PA than a typical prescription call, even though total volume is still a small share of your phone traffic.
• Route GLP-1 calls with insurance/PA context attached from the start. Because coverage and authorization drive so much of the friction, capturing that context on the first call (rather than a callback) shortens the whole cycle.
• Don’t expect a flood — expect a steady, slightly growing category. The July–August 2026 uptick (to ~0.75–0.83% of volume) is real but early; treat it as a category to monitor quarterly, not a volume spike to staff up for immediately.
• Track it separately from general refill volume. Because the administrative profile is genuinely different (more insurance and PA, less plain billing), lumping GLP-1 calls into an undifferentiated “refills” category obscures the pattern that actually drives the extra handle time.
• Budget more staff time per call, not more calls. The category is still a small share of total volume, so the operational risk is not a wave of new call volume — it is that each GLP-1 call, left unstructured, tends to consume more staff time than a typical refill because of the insurance and PA layer stacked on top.

Methodology Note

This analysis uses a first-pass keyword/regex classifier applied to the transcribed RecordingReason field across 3,365,339 patient calls — a fast, no-additional-cost method, not the same as clinically-graded LLM classification. It is directional: it identifies calls that reference GLP-1 medications by name or class, and cross-tabs those against the same keyword-based categories (refill, insurance, prior authorization, billing) used elsewhere in our call-mix analysis. Treat the percentages as a reliable directional signal of call shape and volume, not a clinically adjudicated dataset.

Related Articles

• What 494,000 Patient Phone Calls Reveal About Why Patients Call
• Automated Prescription Refill System for Practices
• Which Patient Calls Can Be Automated? A Medical Practice Guide (2026)
• Top 10 Reasons Patients Call Medical Practices

Discover how CallMyDoc can streamline your practice's administrative tasks, reducing the burden of GLP-1 drug calls. Book a demo today to see our platform in action.